What is GcMAF?

What is GcMAF
GcMAF (Gc Protein derived Macrophage Activating Factor)

occurs naturally in our bodies and instructs macrophages to destroy cancer cells and foreign invaders by activating them, increasing their phagocytic activity.

A macrophage (purple) eats cancer cells

What are Macrophages?

Macrophages (Greek: big eaters) are cells originating from monocytes, a type of white blood cell found in the body. Macrophages function in both non-specific defense (innate immunity) as well as help initiate specific defense mechanisms (adaptive immunity) of vertebrate animals.

Their role is to phagocytize (engulf and then digest) cellular debris and pathogens, either as stationary or as mobile cells. They also stimulate lymphocytes and other immune cells to respond to pathogens. They are specialized phagocytic cells that attack foreign substances, infectious microbes and cancer cells through destruction and ingestion.

A macrophage of a mouse stretching its “arms” (pseudopodia) to engulf two particles, possibly pathogens.

Macrophage Phagocytosis
Steps of a macrophage ingesting a pathogen by phagocytosis.
Under the microscope. Phagocytosis assay with Second Generation GcMAF.
Arrows indicate cells internalized by macrophages.
Tissue Macrophages

Macrophages exist in nearly all tissues throughout the whole body, such as in the skin, the lungs, the gut and the brain. Tissue resident macrophages play critical roles in repair and regeneration.

Macrophages are involved in:

  • Phagocytosis
  • Elimination of dust, allergens and microorganisms
  • Clearance of pathogens and toxins
  • Clearance of blood-borne antigens
  • Recognition and removal of enteric pathogens
  • Tolerance to food antigens and microbiota
  • Antigen capture and presentation to B cells
  • Bone resorption
Function of GcMAF
  • Direct activation of tissue macrophages in the body, such as:
    • Gut/GALT (Gut-Associated Lymphoid Tissue) macrophages
    • Microglia macrophages of the brain
    • Lymphoid tissue in the Waldeyer’s tonsillar ring of the mouth and throat
    • BALT (Bronchus-Associated Lymphoid Tissue)
  • Play a role in the interactions between macrophages and stem cells
  • Increase the rate of maturation of dendritic cells (DCs)
  • Anti-inflammatory effects
Phagocytic Activity Assays
Second Generation GcMAF
Oral Colostrum MAF
Oral Colostrum MAF

Oral colostrum MAF in enteric acid-resistant capsules

  • GcMAF is produced from high quality bovine colostrum
  • Colostrum is very similar to serum – very rich in protein, IgG, IgA and IgM
  • Enteric acid-resistant capsule – can be opened for sublingual administration
  • Oral administration:
  • Easy and convenient to take either orally in the capsule or sublingually as a powder
  • Taken orally on an empty stomach in an enteric acid-resistant capsule
  • Taken sublingually as a powder by opening the capsule and puzng the contents in the mouth for 10-15 minutes
  • Currently registered as a food product in Japan
Oral Colostrum MAF Phagocytic Activity in Gut Macrophage of Mice

Oral Colostrum MAF strongly activated phagocytosis of gut macrophage of mice, similar to that of LPS. GcMAF made from colostrum is very well suited to activation of macrophages in the gut.

Cytokine Production of Mice Peritoneal Macrophages
IL-1β and TNF-α are major inflammatory cytokines
and negatively associated with autoimmune diseases.
Oral Colostrum MAF does not cause the production
of IL-1β and TNF-α pro-inflammatory cytokines
associated with autoimmune diseases.
Th2 Cytokines: Oral GcMAF Experiments in Healthy Dogs
Oral GcMAF suppressed the production of IL-4 and IL-6. These Th2 cytokines are negatively associated with allergic diseases.

Comparison Between 3 Types of GcMAF

Oral Colostrum MAF
  • Developed by Saisei Mirai and Tokushima University in 2014
  • MAF produced from bovine colostrum
  • 1 mg capsule has equivalent activity to 100ng purified GcMAF
  • Enteric acid-resistant capsule for oral administration, powder for sublingual
  • Target Payer‘s Patches/Gut
  • New patent pending production process
  • Registered as a food product in Japan
Oral Colostrum MAF
Tokushima University
Second Generation GcMAF
  • Developed by Saisei Mirai and the University of Tokushima in 2010
  • High concentration (1500 ng/0.5 ml, 1 dose)
  • Significantly higher stability and macrophage activating activity
  • Sterilization process using 0.22 μm filtration system
  • New patented production process
2nd Generation GcMAF
Saisei Mirai center
First Generation GcMAF
  • Developed by Dr Yamamoto in 1991
  • Low concentration (100 ng/0.25 ml, 1 dose)
  • Low stability at room temperature
  • Chemically isolated (purified), sterilization process using 0.22 μm filtration system
  • Uses 25-(OH) Vitamin D3 Affinity Column for production
  • Affinity column has cross-contamination risk when used repeatedly; must be disposable
Vitamin D3 affinity column used for 1st generation
GcMAF production
Comparison of the 3 types of GcMAF in a clinical sezng

Comparison of the 3 types of GcMAF in a clinical sezng. First generation GcMAF has a much lower concentration due to the purification process. Without albumin and uric acid, purified GcMAF is much less stable.

Commonly Observed Clinical Effects of Oral Colostrum MAF

Commonly Observed Clinical Effects

  • Improved sleep, more energy; reduced fatigue
  • Improved digestion, reduced nocturnal urination
  • Improved hair regrowth and reduced hair loss due to natural ageing
  • Improved skin condition & smoothness
  • Improved control or curing of infectious diseases such as virus, bacteria and other pathogens
  • Reduced allergy symptoms, pollinosis and atopy
Current Indications for GcMAF

Current Indications

  • Various infectious diseases
    • Many acute infectious diseases
    • Many chronic infectious diseases
  • Cancer
  • Multiple sclerosis (MS)
  • Rheumatoid arthritis (RA)
  • Lyme disease
  • Chronic fatigue syndrome (CFS)
  • Autism
  • Autoimmune diseases
  • Alopecia, hair loss
  • Atopic dermatitis
  • Pollinosis
  • Skin rejuvenation (repair, anti-aging effects)
  • Psoriasis
  • Warts
  • Acne
Malaria parasite
Ebola virus
Influenza virus
New Possible Indications for GcMAF

New Possible Indications

  • Alzheimer’s disease
  • Dementia
  • Brain degenerative diseases, such as Parkinson’s disease
  • Epilepsy